Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Coherus BioSciences Inc CHRS

Healthcare Biotechnology
Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the research, development and commercialization of immunotherapies to treat cancer. The Company’s immuno-oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor immunologic response and... see more

Recent & Breaking News (NDAQ:CHRS)

Coherus BioSciences to Report First Quarter 2022 Financial Results on May 5th, 2022

GlobeNewswire April 29, 2022

Coherus and Junshi Biosciences Announce PD-1 Inhibitor Toripalimab Granted Orphan Drug Designation for Small Cell Lung Cancer in the United States

GlobeNewswire April 14, 2022

Coherus and Junshi Biosciences Present Results of Phase 3 Study of Toripalimab in First Line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma at 2022 AACR Annual Meeting

GlobeNewswire April 8, 2022

Coherus BioSciences Announces New Employment Inducement Grants

GlobeNewswire April 5, 2022

Coherus Highlights Anticipated New Product Launches and Immuno-oncology Growth Strategy at Analyst Day Event

GlobeNewswire March 29, 2022

Coherus BioSciences to Highlight New Product Pipeline, Cancer Immunotherapy Development Plans at March 29, 2022 Analyst Day Event

GlobeNewswire March 22, 2022

Coherus BioSciences Appoints Rosh Dias, MD, MRCP, Chief Medical Officer

GlobeNewswire March 15, 2022

Junshi Biosciences and Coherus Announce Presentation of Positive Results from CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer, at March ASCO Plenary Series

GlobeNewswire March 15, 2022

Coherus Management to Present at Upcoming Investor Conferences

GlobeNewswire March 4, 2022

Coherus and Junshi Biosciences Announce Positive Results from Phase 3 Esophageal Cancer Study of Toripalimab Published in Cancer Cell

GlobeNewswire March 4, 2022

Coherus BioSciences Reports Fourth Quarter and Full Year 2021 Results

GlobeNewswire February 17, 2022

Coherus Names Paul Reider Chief Commercial Officer

GlobeNewswire February 15, 2022

Coherus BioSciences Announces New Employment Inducement Grants

GlobeNewswire February 14, 2022

Coherus BioSciences to Report Fourth Quarter and Full Year 2021 Financial Results on February 17th, 2022

GlobeNewswire February 11, 2022

Coherus BioSciences Appoints Health Care Payer Expert Lee N. Newcomer, M.D., to Board of Directors

GlobeNewswire February 7, 2022

Coherus and Junshi Biosciences Expand Immuno-Oncology Collaboration to Include TIGIT-Targeted Antibody

GlobeNewswire January 10, 2022

Coherus BioSciences Secures Credit Financing with Pharmakon Advisors

GlobeNewswire January 7, 2022

Coherus BioSciences Management to Present at the 40th Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 4, 2022

Coherus Announces U.S. FDA Approval of YUSIMRY(TM) (adalimumab-aqvh)

GlobeNewswire December 20, 2021

Coherus BioSciences Appoints Theresa LaVallee, Ph.D., Chief Development Officer

GlobeNewswire December 17, 2021